VHH antibody targeting the chemokine receptor CX3CR1 inhibits progression of atherosclerosis

References

• Imai T, Hieshima K, Haskell C, Baba M, Nagira M, Nishimura M, Kakizaki M, Takag IS, Nomiyama H, Schall TJ, et al. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell. 1997;91:521–12. doi:https://doi.org/10.1016/S0092-8674(00)80438-9.
   PubMed Web of Science ®Google Scholar
• Landsman L, Bar-On L, Zernecke A, Kim KW, Krauthgame R, Shagdarsuren E, Lira SA, Weissman IL, Weber C, Jung S. CX3CR1 is required for monocyte homeostasis and atherogenesis by promoting cell survival. Blood. 2009;113(4):963–72. doi:https://doi.org/10.1182/blood-2008-07-170787.
   PubMed Web of Science ®Google Scholar
• Stolla M, Pelisek J, von Brühl ML, Schäfer A, Barocke V, Heider P, Lorenz M, Tirniceriu A, Steinhart A, Bauersachs J, et al. Fractalkine is expressed in early and advanced atherosclerotic lesions and supports monocyte recruitment via CX3CR1. PLoS One. 2012;7(8):e43572. doi:https://doi.org/10.1371/journal.pone.0043572.
   PubMed Web of Science ®Google Scholar
• Bazan JF, Bacon KB, Hardiman G, Wang W, Soo K, Rossi D, Greaves DR, Zlotnik A, Schall TJ. A new class of membrane-bound chemokine with a CX3C motif. Nature. 1997;385(6617):640–44. doi:https://doi.org/10.1038/385640a0.
   PubMed Web of Science ®Google Scholar
• McDermott DH, Fong AM, Yang Q, Sechler JM, Cupples LA, Merrell MN, Wilson PW, D’Agostino RB, O’Donnell CJ, Patel DD, et al. Chemokine receptor mutant CX3CR1-M280 has impaired adhesive function and correlates with protection from cardiovascular disease in humans. J Clin Invest. 2003;111(8):1241–50. doi:https://doi.org/10.1172/JCI16790.
   PubMed Web of Science ®Google Scholar
• Ghilardi G, Biondi ML, Turri O, Guagnellini E, Scorza R. Internal carotidartery occlusive disease and polymorphisms of fractalkine receptor CX3CR1: a genetic risk factor. Stroke. 2004;35(6):1276–79. doi:https://doi.org/10.1161/01.STR.0000128528.56009.d4.
   PubMed Web of Science ®Google Scholar
• Lesnik P, Haskell CA, Charo IF. Decreased atherosclerosis in CX3CR1-/-mice reveals a role for fractalkine in atherogenesis. J Clin Invest. 2003;111(3):333–40. doi:https://doi.org/10.1172/JCI15555.
   PubMed Web of Science ®Google Scholar
• Combadière C, Potteaux S, Gao JL, Esposito B, Casanova S, Lee EJ, Debré P, Tedgui A, Murphy PM, Mallat Z. Decreased atherosclerotic lesion formationin CX3CR1/apolipoprotein E double knockout mice. Circulation. 2003;107(7):1009–16. doi:https://doi.org/10.1161/01.CIR.0000057548.68243.42.
   PubMed Web of Science ®Google Scholar
• Karlström S, Nordvall G, Sohn D, Hettman A, Turek D, Åhlin K, Kers A, Claesson M, Slivo M, Lo-Alfredsson Y, et al. Substituted 7-Amino-5-thio-thiazolo[4,5-d]pyrimidines as potent and selective antagonists of the fractalkine receptor (CX3CR1). J Med Chem. 2013;56:3177–90. doi:https://doi.org/10.1021/jm3012273.
   PubMed Web of Science ®Google Scholar
• Dorgham K, Ghadiri A, Hermand P, Rodero M, Poupel L, Iga M, Hartley O, Gorochov G, Combadière C, Deterre P. An engineered CX3CR1 antagonist endowed with anti- inflammatory activity. Leukoc Biol. 2009;86:903–11.
   PubMed Web of Science ®Google Scholar
• Labrijn AF, Aalberse RC, Schuurman J. When binding is enough: nonactivating antibody formats. Curr Opin Immunol. 2008;20:479–585. doi:https://doi.org/10.1016/j.coi.2008.05.010.
   PubMed Web of Science ®Google Scholar
• Hoefman S, Ottevaere I, Baumeister J, Sargentini-Maier ML. Pre-clinical intravenous serum pharmacokinetics of albumin binding and non-half-life extended VHHs. Antibodies. 2015;4:141–56. doi:https://doi.org/10.3390/antib4030141.
   Web of Science ®Google Scholar
• Wong B, Wong D, McManus BM. Characterization of fractalkine (CX3CL1) and CX3CR1 in human coronary arteries with native atherosclerosis, diabetes mellitus, and transplant vascular disease. Cardio Path. 2002;11:332–38. doi:https://doi.org/10.1016/S1054-8807(02)00111-4.
   PubMed Web of Science ®Google Scholar
• Yadav S, Laue TM, Kalonia DS, Singh SN, Shire SJ. The influence of charge distribution on self-association and viscosity behavior of monoclonal antibody solutions. Mol Pharm. 2012;9:791–802. PMID:22352470. doi:https://doi.org/10.1021/mp200566k.
   PubMed Web of Science ®Google Scholar
• Banik S, Laing C, Doranz BJ. Tools for studying membrane protein targets. Genetic Engineering & Biotechnology News; 2009 Jan 22–23.
   Google Scholar
• Liu H, Jiang D. Fractalkine/CX3CR1 and atherosclerosis. Clinica Chimica Acta. 2011;412:1180–86. doi:https://doi.org/10.1016/j.cca.2011.03.036.
   PubMed Web of Science ®Google Scholar
• Singh S, Waterman A, Depla E, Laeremans T, Van Hoorick D, Ververken D. WO2013130381A1. 2013.
   Google Scholar
• Nguyen VK, Desmyter A, Muyldermans S. Functional heavy-chain antibodies in camelidae. Adv Immunol. 2001;79:261–96.
   PubMed Web of Science ®Google Scholar
• Ghahroudi MA, Desmyter A, Wyns L, Hamers R, Muyldermans S. Selection and identification of single domain antibody fragments from camel heavy-chain antibodies. FEBS Lett. 1997;414:521–26. doi:https://doi.org/10.1016/S0014-5793(97)01062-4.
   PubMed Web of Science ®Google Scholar
• Maussang D, Mujic-Delic A, Descamps F, Stortelers C, Vanlandschoot P, Walsum M, Vischer H, van Roy M, Vosjan M, Gonzalez-Pajuelo M, et al. Llama-derived single variable domains (nanobodies) directed aganist chemokine receptor CXCR7 reduce head and neck cancer cell growth in vivo. J Biol Chem. 2013;288:29562–72. doi:https://doi.org/10.1074/jbc.M113.498436.
   PubMed Web of Science ®Google Scholar
• Veugelen S, Dewilde M, De Strooper B, Chavez-Gutierrez L. Screening and characterization strategies for nanobodies targeting membrane proteins. Methods Enzymol. 2017;584:59–88.
   PubMed Web of Science ®Google Scholar
• Lo M-C, Aulabaugh A, Jin G, Cowling R, Bard J, Malamas M, Ellestad G. Evaluation of fluorescence-based thermal shift assays for hit identification in drug discovery. Anal Biochem. 2004;332:153–59. doi:https://doi.org/10.1016/j.ab.2004.04.031.
   PubMed Web of Science ®Google Scholar
• Vincke C, Loris R, Saerens D, Martinez-Rodriguez S, Muyldermans S. General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold. J Biol Chem. 2009;284:3273–84. doi:https://doi.org/10.1074/jbc.M806889200.
   PubMed Web of Science ®Google Scholar
• Rahbarizadeh F, Rasaee MJ, Forouzandeh M, Allameh -A-A. Over expression of anti-MUC1 single-domain antibody fragments in the yeast Pichia pastoris. Mol Immunol. 2006;43:426–35. doi:https://doi.org/10.1016/j.molimm.2005.03.003.
   PubMed Web of Science ®Google Scholar
• Singh S, Kroe-Barrett R, Canada K, Zhu X, Sepulveda E, Wu H, He Y, Raymond E, Ahlberg J, Frego L, et al. Selective targeting of the IL23 pathway: generation and characterization of a novel high-affinity humanized anti-IL23A antibody. MAbs. 2015;7:778–91. doi:https://doi.org/10.1080/19420862.2015.1032491.
   PubMed Web of Science ®Google Scholar